2005
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia
Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, DeGroot A, Stringer EM, Acosta EP, Goldenberg RL, Vermund SH. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS 2005, 19: 1309-1315. PMID: 16052086, PMCID: PMC2745046, DOI: 10.1097/01.aids.0000180102.88511.7d.Peer-Reviewed Original ResearchConceptsMother-infant pairsHIV testingCord bloodSurveillance populationAntenatal HIV testingPerinatal HIV preventionProportion of HIVChild HIV transmissionHIV test resultsMain outcome measuresNewborn cord bloodHIV prevention programsHIV serologyInfant dosePublic sector facilitiesSeropositive womenAntenatal careHIV transmissionPrescribed regimenCascade of eventsLabor onsetPopulation effectivenessSurveillance periodHIV preventionOutcome measures
2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
Stringer J, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17: 1659-1665. PMID: 12853748, PMCID: PMC2745973, DOI: 10.1097/00002030-200307250-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBreast FeedingDrug Administration ScheduleFemaleHIV InfectionsHIV SeropositivityHumansInfant, NewbornInfectious Disease Transmission, VerticalLabor, ObstetricNevirapineObstetric Labor ComplicationsPregnancyPregnancy Complications, InfectiousProspective StudiesReverse Transcriptase InhibitorsRisk FactorsTime FactorsConceptsPerinatal HIV transmissionHIV transmissionInfant HIV infection statusNeonatal single-dose nevirapineMaternal drug doseSingle-dose nevirapineHIV infection statusProspective cohort studyPerinatal transmission rateOnset of laborMain outcome measuresMean drug concentrationWeeks of lifeRisk of transmissionNVP levelsNVP prophylaxisNVP syrupObstetrical clinicPerinatal transmissionCohort studyOral doseViral loadPregnant womenPolymerase chain reactionRisk factors